Craft

Impel Pharmaceuticals

Stock Price

$0

2024-02-16

Market Capitalization

$5.8 M

2024-02-15

Revenue

$12.7 M

FY, 2022

Impel Pharmaceuticals Summary

Company Summary

Overview
Impel Pharmaceuticals (formerly known as Impel NeuroPharma) is a pharmaceutical company that develops and commercializes therapies for patients suffering from central nervous system diseases. Its technology targets the vascular-rich upper nasal cavity and provides rapid absorption, consistent drug biodistribution. The company specializes in the treatment of such diseases as migraine, autism spectrum disorder, and Parkinson's disease.
Type
Public
Status
Active
Founded
2008
HQ
Seattle, WA, US | view all locations
Website
https://impelpharma.com/
Cybersecurity rating
Sectors

Key People

  • John Hoekman

    John Hoekman, Chief Technology & Development Officer

  • Michael W. Kalb

    Michael W. Kalb, Chief Financial Officer

  • Leonard S. Paolillo

    Leonard S. Paolillo, Chief Commercial Officer

  • Lynn Gold

    Lynn Gold, Senior VP of Regulatory

LocationsView all

1 location detected

  • Seattle, WA HQ

    United States

    Waterfront Research Center, 201 Elliott Ave W #260

Impel Pharmaceuticals Financials

Summary Financials

Revenue (Q3, 2023)
$5.0M
Gross profit (Q3, 2023)
$2.8M
Net income (Q3, 2023)
($13.8M)
Cash (Q3, 2023)
$239.0K
EBIT (Q3, 2023)
($12.8M)
Enterprise value
$116.5M

Footer menu